An overview: Radiotracers and nano-radiopharmaceuticals for diagnosis of Parkinson's disease

Ozolmez N., SİLİNDİR GÜNAY M., VOLKAN SALANCI B.

Applied Radiation and Isotopes, cilt.203, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 203
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1016/j.apradiso.2023.111110
  • Dergi Adı: Applied Radiation and Isotopes
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), Chemical Abstracts Core, Chimica, Compendex, EMBASE, Food Science & Technology Abstracts, INSPEC, MEDLINE, Pollution Abstracts
  • Anahtar Kelimeler: Nuclear imaging, Parkinson's disease, PET, Radiolabeled nanocarriers, Radiopharmaceuticals, SPECT
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Parkinson's disease (PD) is a widespread progressive neurodegenerative disease. Clinical diagnosis approaches are insufficient to provide an early and accurate diagnosis before a substantial of loss of dopaminergic neurons. PET and SPECT can be used for accurate and early diagnosis of PD by using target-specific radiotracers. Additionally, the importance of BBB penetrating targeted nanosystems has increased in recent years. This article reviews targeted radiopharmaceuticals used in clinics and novel nanocarriers for research purposes of PD imaging.